Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

NORML

MARCH 23, 2020

Yet despite these and other claims , including those spreading on social media , there is as of yet no substantiated clinical data supporting either the prophylactic or therapeutic use of cannabis products in the treatment of COVID-19. A greater discussion of these cannabis safety guidelines are available from NORML here.).

CBD 349

CBD Therapy Treatment Packaging 349

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 105

Consumption Patients Research and Development Data 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Veriheal

MAY 30, 2023

But what if a safe and effective complementary plant-based treatment was widely available to alleviate cancer pain? A new 2023 study published in BMJ Supportive & Palliative Care suggests that cannabis could be the answer millions of cancer patients have been looking for. in cancer patients undergoing anticancer treatment, 50.7%

Medicine 96

Medicine Treatment Patients Data 96

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). Patient-reported outcomes. PROGRAMME.and.ABSTRACTS. Improved quality of life.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

SpeedWeed

FEBRUARY 21, 2021

The human primary blood cell screens performed at MSU are state-of-the-science models for evaluating the effects of compounds on the human immune system,” said Kaminski, director of the Institute for Integrative Toxicology, Professor of Pharmacology & Toxicology, and director of MSU’s Center for Research on Ingredient Safety.

Treatment 52

Treatment Research and Development Cannabinoids Data 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Veriheal

SEPTEMBER 23, 2021

Fortunately, one such man, Levi Barker, provided us with some much-needed insight into what the substance is, how it is used in treatment, and more. Many of us have more in our minds than we need… Veriheal: Can you walk us through a typical iboga treatment? One could even say that iboga provides holistic healing.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Chronicles

MAY 22, 2019

SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.

Medicine 140

Medicine Research and Development Data Collective 140

Veriheal

NOVEMBER 21, 2023

Quemarr’s transformative approach to diabetes treatment offers patients a less intrusive alternative to conventional insulin treatments. The buddie can be paired with a mobile app that tracks consumption, correlating it with health data from devices like WHOOP, Apple Watch, or Fitbit.

Research and Development 93

Research and Development Consumption Education Data 93

TheAnswerPage

JULY 17, 2022

In 2017, researchers performed an analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Their findings included the following: “The average daily dose ranged between 1 and 50 mg/kg, with treatment length from 3 to 12 months (mean 6.2 12 September 2018.

Epilepsy 72

Epilepsy Extraction Treatment CBD 72

Veriheal

AUGUST 12, 2021

Patients who suffer from epilepsy , which affects some 3.4 Pharmaceutical CBD is currently a restricted prescription medication, and insurance coverage is often limited to only those patients with the specific approved indications. Researchers Analyzed Survey Results from 280 Epilepsy Patients.

Epilepsy 58

Epilepsy Pharmaceutical Patients Sleep 58

The Joint Blog

MARCH 16, 2020

According to a new study published in the journal Phytotherapy Research, the sustained use of marijuana in patients with chronic conditions is associated with quality of life maintenance and a lack of cognitive decline. Around 90% of participants self-medicated with cannabis daily. Participants were followed-up at baseline, 4, 8 and 12?

Patients 49

Patients Marijuana Epilepsy Treatment 49

Veriheal

AUGUST 22, 2022

Based on the details of a June 21 press release, the trials—which are taking place in Johannesburg—are the first ethically approved studies exploring the suitability and safety of using cannabis as a substitute for opioid pain relievers. . ” Dr. S tudy subjects must be willing and ready to substitute opioids with cannabis. “We

Clinical Trials 111

Clinical Trials Chronic Pain Hydroponic Strains 111

The Joint Blog

JANUARY 21, 2020

Marijuana use is associated with subjective benefits in patients with Tourette Syndrome (TS), according to a new study published in the journal Cannabis and Cannabinoid Research. The study is titled Treatment of Gilles de la Tourette Syndrome in cannabis-based medicine: Results from a retrospective analysis and online survey.

Patients 29

Patients Marijuana Data Treatment 29

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Policy decisions related to taxation, zoning, and advertising also impact the industry’s operations and growth trajectory.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

The Cannigma

OCTOBER 21, 2021

Still, many patients report that cannabis helps them to feel more in control of their symptoms, leading to important questions. While there has been little systematic research on using cannabis for ADHD, many patients with the condition report positive effects from using cannabis. Can cannabis help with ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 1, 2021

This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). About Awakn Life Sciences Corp.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

APRIL 12, 2019

A patient in Alberta spending $600 (~€397) per month on medical cannabis will pay 24.3% ($145.80) in tax. For most Canadian patients, including myself, this means 24.3% CFAMM’s goal is to support medical cannabis patients, improve their outcomes and enable them to obtain fair and safe access to their medication.

Access 45

Access Patients Marijuana Medicine 45

The Joint Blog

JANUARY 3, 2020

Marijuana-based medicines “might be effective and safe in the treatment of tics and comorbidities” in those with Gilles de la Tourette Syndrome, according to a new study published in the journal Cannabis and Cannabinoids Research and e-published by the National Institute of Health. ” Dosages of all CBM varied markedly.

Data 49

Data Treatment Marijuana Patients 49

Cannabis Law Report

SEPTEMBER 29, 2021

With more states legalizing cannabis for medical and recreational use, TCI recognizes the critical role that education plays in reducing patient adverse outcomes and ensuring the safe use of cannabis. TCI was founded by Drs. About The Cannabinoid Institute ??

Cannabinoids 52

Cannabinoids Education Patients Safety 52

Cannabis Law Report

JULY 12, 2021

CSE: MSET) revealed additional preclinical data showing strong efficacy and improved safety in a head-to-head comparison with psilocybin. NEO: MEDI) (“Ketamine One” or the “Company”) plans to bring psychedelic treatments to patients and overcome some of the critical barriers in administering mental health treatments with technology.

Treatment 66

Treatment Decriminalization Pharmaceutical Data 66

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. The disease has no approved cure and most current treatments are directed towards symptomatic relief.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

SpeedWeed

MARCH 6, 2021

Public safety at issue. Proponents of these THC caps—who are often the same politicians who stood against legalization and lost—contend that limiting THC levels will increase public safety. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients.

THC 52

THC Patients Law Chronic Pain 52